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Background/aim: The purpose of this experimental study was to investigate the role of lipoprotein-associated phospholipase-A2 (LpPLA2) in the diagnosis of acute mesenteric ischemia (AMI) in the early stage.
Materials and methods: Twenty-seven New Zealand rabbits were randomly divided into 3 groups in this study. Blood specimens were
obtained from the groups at hours 0, 1, 3, and 6. Using the blood samples drawn from all groups, Lp-PLA2 and C-reactive protein (CRP)
parameters were investigated.
Results: There was a significant rise in the levels of both Lp-PLA2 and CRP starting at hour 1 (P < 0.05) (hour 1; Lp-PLA2, P = 0.003) in
the ischemia group. In the sham group, the levels of Lp-PLA2 and CRP started to rise at hour 3 (P < 0.05) (hour 3; Lp-PLA2, P = 0.011).
At hour 6 of ischemia, the area under the ROC curve was 100%, and the cut-off value of 63.91 ng/mL revealed a sensitivity of 88% and
a specificity of 100% for Lp-PLA2.
Conclusion: These findings showed the role of serum Lp-PLA2 and CRP levels in the early diagnosis of AMI. Thus, further studies are
needed to describe the role of Lp-PLA2 in the early diagnosis of AMI.
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1. Introduction
Acute mesenteric ischemia (AMI), which is associated with
a high mortality rate, should be considered as a causative
clinical condition because of its difficult diagnosis (1–3).
The symptoms and physical examination findings of
AMI are usually nonspecific and radiological changes in
the early stage are nondiagnostic. AMI comprises 1%–
2% of all gastrointestinal disorders and has a very high
mortality rate (71%). Research shows that AMI has severe
complications and may be fatal (2,3).
AMI is a life-threatening disorder so that early
diagnosis of AMI is very important. However, there are no
sensitive and specific biomarkers for use in early diagnosis.
Research on atherosclerosis shows that inflammation
has a significant role in the disease and many studies have
focused on it. Lipoprotein-associated phospholipase-A2
(Lp-PLA2), which is a current biomarker of inflammation
and atherosclerosis, is important for diagnosis and its
importance is growing. Lp-PLA2 is a member of the
phospholipase A2 family. This enzyme is released by
inflammatory myeloid cells that rapidly accumulate in the
lesion and are associated with atherogenic lipoproteins in
* Correspondence: drtarikacar@gmail.com
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circulation (4). Lp-PLA2 hydrolyzes the proinflammatory
oxidized phospholipids that cause endothelial dysfunction,
plaque inflammation, and formation of necrotic focus
within the plaque. Furthermore, Lp-PLA2 is thought to
be responsible for the association between an increased
inflammatory response in the intima and oxidative change
of low-density lipoproteins (LDLs) (5). There are many
studies about the effects of Lp-PLA2 on atherosclerosis.
However, as far as we know, there is no study in the
literature on the association of Lp-PLA2 with AMI, which
is an atherosclerotic disorder.
The purpose of this experimental study was to
determine whether Lp-PLA2 is of diagnostic value for
AMI. Previous studies revealed that Lp-PLA2 is a novel
biomarker for inflammation. The results of Lp-PLA2 were
compared with those of C-reactive protein (CRP), which is
a nonspecific inflammatory marker and increases in AMI.
2. Materials and methods
This experimental study was approved by the Ethics
Committee for Experimental Animals, Center for Research
and Application in Experimental Medicine of Necmettin
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Erbakan University, on 20 January 2012, being registered
with number 2012-011. The study was performed at the
Center for Research and Application in Experimental
Medicine of Necmettin Erbakan University in May 2012.
All animals were kept and fed by specialized animal care
workers under physical conditions recommended by
international guidelines.
We applied to the University Ethics Committee to use
10 rabbits in each group in the study. However, the ethics
committee allowed 7 rabbits for the control group and
10 rabbits for each of the other groups. The rabbits were
randomly divided into three groups. However, because a
rabbit died in the ischemia group in the very beginning
of the study, that rabbit was excluded from the study. The
study carried on with 7 rabbits in the control group, 10
in the sham group, and 9 in the ischemia group, adding
up to a total of 26 adult New Zealand rabbits weighing
2500–3000 g each.
All groups received 50 mg/kg ketamine and 15 mg/
kg xylazine i.m. in the hind leg. Following anesthesia,
vascular access was established in the dorsal ear vein with
an Intracath 22G for blood drawing and liquid injections.
For the biochemical tests, each time, 5 mL of blood was
drawn into gel-containing vacutainer tubes at hours 0, 1,
3, and 6. Following each blood draw, 5 mL of saline was
injected into the rabbit through the same vein.
No tissue specimens were obtained from the rabbits in
the control group (group I).
In the sham group (group II), after the first blood
specimen was obtained, the abdominal wall of each rabbit
was shaved and cleaned with 10% povidone-iodine. An
abdominal laparotomy was performed with a midline
incision. Following laparotomy, the abdominal wall and
the peritoneum were closed with 2/0 silk thread sutures.
No tissue specimens were obtained from the rabbits in this
group either.
In the ischemia group (group III) the same preparations
carried out on the rabbits as in the sham group were
performed. After having obtained blood specimens at hour
0, each rabbit underwent laparotomy through a midline
incision, and the superior mesenteric artery was ligated
with a 0 silk thread. The peritoneum and the abdominal
wall were then closed up with 2/0 silk sutures. At the end of
hour 6 of ischemia, the rabbits were euthanized with highdose ketamine, and 10-cm-long specimens were obtained
from the distal ileum for histopathological examination.
The tissue specimens were washed with sterile saline and
kept in 10% formaldehyde solution.
2.1. Collection of specimens
First 5 mL of blood was obtained from every rabbit and
placed in tubes containing EDTA. The blood specimens
were then centrifuged at 3000 rpm at 4 °C for 10 min, and
the plasma that was separated with this cold centrifugation

was placed in microcentrifuge tubes (Eppendorf) and
stored at –80 °C until the time of use. The 10-cm-long
specimens of the distal ileum that had been obtained
for histopathological examination, in the line of order,
were placed in routine xylol-alcohol solution, embedded
in paraffin blocks, washed with saline, and fixed in 10%
formaldehyde solution.
2.2. Biochemical method
Commercial kits and ELISA were used for biomarker
measurements. For Lp-LPA2 measurements, the scientific
research special Eastbiopharm Rabbit Lp-PLA2 ELISA kit
(Lot No: 20121024) was used, and for CRP measurements,
the scientific research special Eastbiopharm Rabbit LpPLA2 ELISA kit (Lot No: 20121024) was used.
2.3. Histopathological examination and evaluation
At the end of the 6-hour ischemia, blood specimens were
obtained from the rabbits, and then the rabbits were
euthanized. Intestinal specimens for histopathological
examination were obtained from the distal ileum. The
intestinal tissue specimens were consistent with ischemia
macroscopy. The 10-cm-long specimens from the distal
ileum were first washed with saline and then fixed in
formaldehyde solution. After passing through routine
xylol-alcohol series and paraffin embedding, the tissue
specimens were cut into 5-µm sections. The sections
were stained with hematoxylin–eosin and then studied
under 100× light microscope magnification to score the
intestinal mucosal injury on a scale described by Chiu et
al.(6).
Scale of mucosal injury
Grade 0: Normal mucosal villi
Grade 1: Extension of the subepithelial space, capillary
congestion at the apex of villi
Grade 2: Subepithelial congestion extending to the
base of villi
Grade 3: Ulcerations at the apex of some villi, extensive
subepithelial congestion
Grade 4: Villus ulcerations, dilated capillaries in the
lamina propria
Grade 5: Digestion and disintegration of the lamina
propria, hemorrhage, and ulceration
2.4. Statistical analysis
All of the obtained data were recorded on ready tables.
SPSS 16.0 was used for the statistical analysis. The Kruskal–
Wallis variance analysis and the Mann–Whitney U test
were utilized for the comparison of groups. The change
in biomarkers over time was evaluated using Friedman’s
test. Spearman’s correlation test was performed for the
determination of association between Lp-LPA2 and CRP
levels. Results were considered to be statistically significant
at P < 0.05. The area under the receiver operating
characteristic (ROC) curve was used as a performance
measure. The results are presented in tables and graphics.
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Table 2. The changes of markers in time.
Group
Control

Sham

Ischemia

Friedman’s test

P

L0-L1-L3-L6

0.478

C0-C1-C3-C6

0.069

L0-L1-L3-L6

0.003

L0-L1

0.527

L0-L3

0.011

C0-C1-C3-C6

0.000

L0-L1-L3-L6

0.000

L0-L1

0.003

C0-C1-C3-C6

0.000

0.7
Serum CRP levels (µg/mL)

Serum Lp - PLA 2 levels (ng/mL)

3. Results
The serum Lp-PLA2 and CRP levels were measured in the
blood samples at hours 0, 1, 3, and 6 in all rabbits (n =
26). The comparison of the groups in terms of P values of
serum Lp-PLA2 and CRP levels is shown in Table 1, and
the change in time in serum Lp-PLA2 levels is presented
in Figure 1.
There were significant differences in the Lp-PLA2 levels
at hours 1, 3, and 6 among the control, sham, and ischemia
groups (P < 0.05) (Table 1). It was observed that there were
significant differences in the Lp-PLA2 levels at hours 3 and
6 between the control and sham groups (P < 0.05), and
at hours 1, 3, and 6 between the control and the ischemia
groups, and between the sham and the ischemia groups (P
< 0.05) (Table 1).
There were significant differences in the CPR levels
at hours 1, 3, and 6 between the sham and the ischemia
groups (P < 0.05) (Table 1), between the control and the
ischemia groups, and between the sham and the ischemia
groups (P < 0.05) (Table 1). The comparison of the groups
in terms of P values of serum Lp-PLA2 and CRP levels is
shown in Table 2 and the change in the CRP level over
time is presented in Figure 2.
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Figure 2. Time-dependent changes of serum CRP levels.
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Figure 1. Time-dependent changes of serum Lp-PLA₂ levels.

There was no difference between the Lp-PLA2 and CRP
levels at hours 0, 1, 3, or 6 in the control group (P > 0.05).
The changes in serum Lp-PLA2 and CRP levels over time
in the groups are shown in Table 3.
In the sham group, there were differences between the
Lp-PLA2 levels at hours 0, 1, 3, and 6 (P < 0.05); there was
no difference between the levels at hours 0 and 1, but there

Table 1. Comparison of Lp-PLA2 and CRP levels between groups.
L0

L1

L3

L6

C0

C1

C3

C6

0.742

0.007

0.001

0.001

0.104

0.045

0.001

0.001

Con-Sh, P

0.463

1.000

0.003

0.032

0.060

0.920

0.020

0.003

Con-Isc, P

0.711

0.010

0.003

0.001

0.419

0.048

0.001

0.001

Sh-Isc, P

0.462

0.006

0.001

0.001

0.117

0.026

0.001

0.001

Kruskal–Wallis
Con-Sh-Isc, P
Mann–Whitney U

L0: Hour 0 Lp-PLA2; L1: Hour 1 Lp-PLA2; L3: Hour 3 Lp-PLA2; L6: Hour 6 Lp-PLA2.
C0: Hour 0 CRP; C1: Hour 1 CRP; C3: Hour 3 CRP; C6: Hour 6 CRP. P < 0.05 value is considered significant. Con = Control group;
Sh = Sham group; Isc = Ischemia group.
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Table 3. Mean, median, and standard error values of Lp-PLA2 and CRP in groups.
Group

Control

Sham

Ischemia

Mean

Median

Mean

Median

Mean

Median

L0

40.49 ± 0.26

40.52

39.83 ± 3.2

40.64

44.24 ± 9.08

47.04

L1

41.82 ± 0.57

41.76

41.32 ± 5.66

41.47

58.73 ± 12.86

61.24

L3

40.36 ± 1.88

39.33

30.43 ± 7.89

31.57

68.96 ± 15.60

70.06

L6

41.02 ± 1.44

40.38

34.27 ± 6.27

33.52

82.04 ± 12.21

84.72

C0

0.39 ± 0.02

0.40

0.37 ± .02

0.37

0.39 ± .02

0.39

C1

0.40 ± 0.02

0.41

0.41 ± .02

0.41

0.47 ± .07

0.45

C3

0.40 ± 0.02

0.41

0.43 ± .02

0.43

0.52 ± .05

0.51

C6

0.40 ± 0.01

0.41

0.46 ± .03

0.46

0.62 ± .04

0.62

L0: Hour 0 Lp-PLA2; L1: Hour 1 Lp-PLA2; L3: Hour 3 Lp-PLA2; L6: Hour 6 Lp-PLA2; C0: Hour 0 CRP; C1: Hour 1 CRP; C3: Hour 3
CRP; C6: Hour 6 CRP. The unit weight of Lp-PLA2 is ng/mL; and the unit weight for CRP is µg/mL ± standard deviation.

was a difference between the levels at hours 0 and 3. There
were also differences between the CRP levels at hours 0, 1,
3, and 6 (P < 0.05) (Table 2).
In the ischemia group, there were differences between
the Lp-PLA2 levels at hours 0, 1, 3, and 6 (P < 0.05), starting
at hour 1. The differences were observed between the CRP
levels at hours 0, 1, 3, and 6 (P < 0.05), also starting at hour
1 (Table 2).
A positive correlation was observed between the LpPLA2 and CRP levels (r² = 0.737, P < 0.001) (Figure 3).
The ROC curve was used to measure and compare
performance. In the ischemia group, the area under the
curve for Lp-PLA2 at hour 6 was 100%. The cut-off value of
63.91 ng/mL provided a sensitivity of 88% and a specificity
of 100% (Figure 4).
According to the results of histopathological
examination of tissue specimens from the distal ileum, the

mucosal injury was of grade 5 in 5 specimens and of grade
4 in 4 specimens (Figure 5).
4. Discussion
The prognosis of patients diagnosed with AMI has
improved with advances in diagnostics such as imaging
techniques and qualified care of intensive care units.
Various biomarkers have been used for the diagnosis of
AMI, but none of these have been specific for AMI, yielding
positive results in local or systemic inflammations. Acosta
(7) reviewed the current parameters used in AMI, in both
humans and animals, but he did not mention Lp-PLA2 as
a parameter.
The most important stage of AMI, for certain, is
mesenteric ischemia requiring prompt diagnosis before
intestinal infarction develops. In view of the high fatality
rates, studies on diagnostic tests for AMI have accelerated
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Figure 3. The relationship between serum Lp-PLA2 and CRP levels (r² = 0.737).
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Figure 4. The ROC curve of Lp-PLA2 at hour 6 of ischemia.

Figure 5. Hemorrhage, ulceration, and necrosis in the lamina
propria (H-E ×100).

in recent years. The common result of all these studies is
that there is still no sensitive and specific biomarker for
clinical use that would indicate the early stage of AMI.
The diagnostic method to be used for AMI in the clinic
should be noninvasive, it should not take long to perform,
and should rapidly give the results.
Lp-LPA2 is used and studied in many disorders such
as oxidative stress, atherosclerosis, coronary artery
disease, cardiac insufficiency, Alzheimer disease, transient
ischemic attack (8), cerebrovascular disorder (9),
allergic lung diseases, HIV-positive patients, intracranial
hemorrhage in preterm infants (10), hypertensive patients,
subarachnoid hemorrhage, nonsmall cell lung cancer (11),
patients with African dengue (12), hemodialysis patients,
diabetes mellitus, multiple sclerosis with immune response
(13), polycystic ovary syndrome (14), systemic sclerosis
(15), nonalcoholic fatty liver disease, high-grade carotid
stenosis with unstable plaque, and metabolic syndrome.
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The studies on Lp-PLA2 have been mainly related to
disorders caused by oxidative stress, atherosclerosis, and
inflammation. Oxidative stress and inflammation are
widely seen in AMI. Lp-PLA2 is accepted as a biomarker
specific for vascular inflammation, and hence it can
increase in AMI as well. Even a small elevation in the
plasma Lp-LPA2 level can indicate the presence of plaque
inflammation and endothelial dysfunction. The Food
and Drug Administration (FDA) has approved the use of
Lp-PLA2 in determining the risk for ischemic attack and
coronary artery disease (16).
Dohi et al. (17) studied the association between plaque
volume and circulatory Lp-PLA2 after percutaneous
coronary intervention in acute coronary syndrome (ACS)
patients and concluded that the levels of circulatory LpPLA2 were associated with changes in plaque volume in
patients with ACS.
Lp-PLA2 has been described as an independent
inflammatory risk biomarker for recurrence of ischemic
stroke and myocardial infarction (16). Rosso et al.
(18) found higher levels of Lp-PLA2 in intracerebral
hemorrhage than in ischemic stroke, and described this
finding as a surprise.
In an experimental study, Dündar et al. (19) compared
the levels of serum ischemia-modified albumin (IMA)
and interleukin-6 (IL-6) in the course of time in cases
with AMI. The authors found significantly higher levels
of serum IMA and IL-6 in the ischemia group than in
the control and the sham groups. Similar to our findings,
this study (19) has found inflammatory markers to be
significant during the inflammatory stage leading up to
AMI.
In our study, Lp-PLA2 levels were increased at the
1st hour period in the ischemia group but a similar
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increase was not observed in the control or sham groups.
Furthermore, in the sham group Lp-PLA2 levels indicated
a small decrease at hour 3. This can be explained by the
antioxidant system. This system was able to overcome
oxidative stress and the inflammatory process, which
develop more lightly and slowly in the sham group
when compared with the ischemia group. These results
demonstrated that increased levels of Lp-PLA2 in the early
stage of AMI can be helpful in diagnosis.
An experimental study on intestinal ischemiareperfusion found that the phospholipase A2 and Lp-PLA2
levels were higher in the group resulting in death following

reperfusion than in the sham group (20). The present
study suggests that Lp-PLA2 increases in the presence of
inflammatory reaction and oxidative stress.
As a result of this study, increased Lp-PLA2 levels
were obtained in AMI. Furthermore, Lp-PLA2 levels
were correlated with CRP, which is another nonspecific
inflammatory biomarker.
The blood Lp-PLA2 levels were increased in the first
hours of AMI. This increase is consistent with the increase
in CRP levels. The results of this study demonstrated that
Lp-PLA2 can be used in the early diagnosis of AMI. More
comprehensive studies on the subject are needed.

References
1.

Sise MJ. Acute mesenteric ischemia. Surg Clin North Am 2014;
94: 165–181.

2.

Yasuhara H. Acute mesenteric ischemia: the challenge of
gastroenterology. Surg Today 2005; 35: 185–95.

3.

Stamatakos M, Stefanaki C, Mastrokalos D, Arampatzi H,
Safioleas P, Chatziconstantinou C, Xiromeritis C, Safioleas
M. Mesenteric ischemia: still a deadly puzzle for medical
community. Tohoku J Exp Med 2008; 216; 197–204.

4.

Zalewski A, Nelson JJ, Hegg L, Macphee C. Lp-PLA2: a new
kid on the block. Clin Chem 2006; 52: 1645–1650.

5.

Lp-PLA(2) Studies Collaboration, Thompson A, Gao P,
Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne
C, Cannon CP, Criqui M et al. Lipoprotein-associated
phospholipase A(2) and risk of coronary disease, stroke, and
mortality: collaborative analysis of 32 prospective studies.
Lancet 2010; 375: 1536–1544.

6.

Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal
mucosal lesion in low-flow states. I. A morphological,
hemodynamic, and metabolic reappraisal. Arch Surg 1970;
101: 478–483.

7.

Acosta S, Nillson T. Current status on plasma biomarkers for
acute mesenteric ischemia. J Thromb Thrombolysis 2012; 33:
355–361.

8.

Delgado P, Chacón P, Penalba A, Pelegri D, García-Berrocoso
T, Giralt D, Santamarina E, Ribó M, Maisterra O, AlvarezSabín J et al. Lipoprotein-associated phospholipase A(2)
activity is associated with large-artery atherosclerotic etiology
and recurrent stroke in TIA patients. Cerebrovasc Dis 2012; 33:
150–158.

9.

Kakkos SK, Tsolakis IA. The emerging role of lipoproteinassociated phospholipase A2 in cerebrovascular disease. Eur J
Vasc Endovasc Surg 2012; 43: 160.

10.

Zhang Q, Cheng XR, Xu SL, Shi ZY, Sheng GY. Association
between platelet-activating factor acetylhydrolase gene
polymorphism and intracranial hemorrhage in preterm
infants. Zhongguo Dang Dai Er Ke Za Zhi 2012; 14: 612–615.

11.

Lo FY, Chen HT, Cheng HC, Hsu HS, Wang YC. Overexpression
of PAFAH1B1 is associated with tumor metastasis and poor
survival in non-small cell lung cancer. Lung Cancer 2012; 77:
585–592.

12.

Restrepo BN, Arboleda M, Ramirez R, Alvarez G. Serum
platelet-activating factor acetylhydrolase activity in dengue
patients of African or mestizo descendency Biomedica 2011;
31: 599–607 (article in Spanish with an abstract in English).

13.

Sternberg Z, Drake A, Sternberg DS, Benedict RH, Li
F, Hojnacki D, Weinstock-Guttmann B, Munschauer FE. LpPLA2: inflammatory biomarker of vascular risk in multiple
sclerosis. J Clin Immunol 2012; 32: 497–504.

14.

Fan P, Liu H, Wang Y, Zhang F, Bai H. Apolipoprotein
E-containing HDL-associated platelet-activating factor
acetylhydrolase activities and malondialdehyde concentrations
in patients with PCOS. Reprod Biomed Online 2012; 24: 197–
205.

15.

Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Sato S.
Clinical significance of circulating platelet-activating factor
acetylhydrolase levels in systemic sclerosis. Arch Dermatol
Res 2012; 304: 203–208.

16.

Gorelick PB. Lipoprotein-associated phospholipase A2 and
risk of stroke. Am J Cardiol 2008; 101: 34F–40F.

17.

Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Ohkawa
R, Nakamura K, Yanagisawa N, Tsuboi S, Ogita M, Yokoyama
K et al. Decreased circulation lipoprotein-associated
phospholipase A2 levels are associated with coronary
plaque regression in patients with acute coronary syndrome.
Atherosclerosis 2011; 219: 907–912.

18.

Rosso C, Rosenbaum D, Pires C, Cherfils C, Koujah
N, Mestari F, Gillet E, Crozier S, Sahli-Amor M, Samson
Y et al. Lipoprotein-associated phospholipase A2 during the
hyperacute stage of ischemic and hemorrhagic strokes. J Stroke
Cerebrovasc Dis 2014; 23: e277–e282.

19.

Dundar ZD, Cander B, Gul M ,Karabulut KU, Girisgin S.
Serum ischemia-modified albumin levels in an experimental
acute mesenteric ischemia model. Academic Emergency
Medicine 2010; 17: 1233–1238.

20.

Kostopanagiotou G, Avgerinos E, Costopanagiotou
C, Arkadopoulos N, Andreadou I, Diamantopoulou K, Lekka
M, Smyrniotis V, Nakos G. Acute lung injury in a rat model
of intestinal ischemia-reperfusion: the potential time depended
role of phospholipases A(2). J Surg Res 2008; 147: 108–116.

125

